1. Market Research
  2. > All Companies
  3. > Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Company (Lilly) is a global healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines in the fields of cardiovascular, diabetes, cancer, neuroscience, critical care, men's health and musculoskeletal. It also provides pet medicine, food-safety products and services to the food animal industry and companion animal health products. Lilly is also has mid-to-late stage pipeline portfolio representing a variety of therapeutic areas including diabetes, cancer, neuroscience and autoimmunity. The company distributes human pharmaceutical and animal health products primarily through independent wholesale distributors.

Eli Lilly and Company Key Recent Developments

Feb 24,2016 Indiana Biosciences Research Institute Announces $100 Million in Grants Supporting Scientific Innovation to Address Metabolic Disease and Poor Nutrition
Feb 23,2016 Major pharma companies sign up to groundbreaking Parkinson’s consortium
Feb 11,2016 Lilly Diabetes Helps Inspiring Students With Type 1 Diabetes Attend College Through Scholarship Donation
Jan 28,2016 Lilly Reports Fourth-Quarter And Full-Year 2015 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Eli Lilly and Company - Key Facts 6
Eli Lilly and Company - Key Employees 7
Eli Lilly and Company - Key Employee Biographies 9
Eli Lilly and Company - Major Products and Services 10
Eli Lilly and Company - Pharmaceutical Pipeline Products Data 12
Eli Lilly and Company, Pipeline Products by Therapy Area 12
Eli Lilly and Company, Pipeline Products by Development Phase 13
Eli Lilly and Company - History 23
Eli Lilly and Company - Company Statement 38
Eli Lilly and Company - Locations And Subsidiaries 41
Head Office 41
Other Locations and Subsidiaries 41
Eli Lilly and Company - Key Manufacturing Facilities 48
Joint Venture 48
Section 2 - Company Analysis 49
Eli Lilly and Company - Business Description 49
Business Description - Animal Health Products 49
Animal Health Products - Overview 49
Animal Health Products - Financials 49
Business Description - Human Pharmaceutical Products 49
Human Pharmaceutical Products - Overview 49
Human Pharmaceutical Products - Financials 50
Eli Lilly and Company - Corporate Strategy 51
Eli Lilly and Company - SWOT Analysis 52
SWOT Analysis - Overview 52
Eli Lilly and Company - Strengths 52
Strength - Emphasis on Research 52
Strength - Established Presence: Endocrinology Product Market 52
Strength - Lilly Oncology 52
Eli Lilly and Company - Weaknesses 53
Weakness - Insufficient Efficacy 53
Weakness - Product Defects 53
Eli Lilly and Company - Opportunities 54
Opportunity - Strategic Collaborations 54
Opportunity - Product Pipeline 54
Opportunity - Strategic Acquisitions 54
Eli Lilly and Company - Threats 55
Threat - Influx of Generics 55
Threat - Product Litigations 55
Threat - Competitive Pressures 55
Eli Lilly and Company - Key Competitors 56
Section 3 - Company Financial Ratios 57
Financial Ratios - Capital Market Ratios 57
Financial Ratios - Annual Ratios 58
Performance Chart 60
Financial Performance 60
Financial Ratios - Interim Ratios 61
Financial Ratios - Ratio Charts 62
Section 4 - Company's Lifesciences Financial Deals and Alliances 63
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 63
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 64
Eli Lilly and Company, Recent Deals Summary 65
Section 5 - Company's Recent Developments 67
Feb 24, 2016: Indiana Biosciences Research Institute Announces $100 Million in Grants Supporting Scientific Innovation to Address Metabolic Disease and Poor Nutrition 67
Feb 23, 2016: Major pharma companies sign up to groundbreaking Parkinson's consortium 68
Feb 11, 2016: Lilly Diabetes Helps Inspiring Students With Type 1 Diabetes Attend College Through Scholarship Donation 69
Jan 28, 2016: Lilly Reports Fourth-Quarter And Full-Year 2015 Results 70
Jan 19, 2016: Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration 77
Jan 05, 2016: Lilly Announces 2016 Financial Guidance, Updates 2015 Expectations 78
Dec 15, 2015: Juan R. Luciano elected to Lilly board of directors 79
Nov 02, 2015: Eli Lilly and Company Announces Expansion of Indianapolis RandD Headquarters 80
Oct 30, 2015: Feds Investigate Lilly Over Drug Pricing Policies 81
Oct 22, 2015: Lilly Reports Third-Quarter 2015 Results, Revises 2015 Financial Guidance 82
Section 6 - Appendix 85
Methodology 85
Ratio Definitions 85
About GlobalData 89
Contact Us 89
Disclaimer 89

List of Tables
Eli Lilly and Company, Key Facts 6
Eli Lilly and Company, Key Employees 7
Eli Lilly and Company, Key Employee Biographies 9
Eli Lilly and Company, Major Products and Services 10
Eli Lilly and Company, Number of Pipeline Products by Therapy Area 12
Eli Lilly and Company, Number of Pipeline Products by Development Stage 13
Eli Lilly and Company, Pipeline Products By Therapy Area and Development Phase 14
Eli Lilly and Company, History 23
Eli Lilly and Company, Subsidiaries 41
Eli Lilly and Company, Key Manufacturing Facilities 48
Eli Lilly and Company, Joint Venture 48
Eli Lilly and Company, Key Competitors 56
Eli Lilly and Company, Ratios based on current share price 57
Eli Lilly and Company, Annual Ratios 58
Eli Lilly and Company, Interim Ratios 61
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 63
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 64
Eli Lilly and Company, Recent Deals Summary 65
Currency Codes 85
Capital Market Ratios 85
Equity Ratios 86
Profitability Ratios 86
Cost Ratios 87
Liquidity Ratios 87
Leverage Ratios 88
Efficiency Ratios 88

List of Figures
Eli Lilly and Company, Pipeline Products by Therapy Area 12
Eli Lilly and Company, Pipeline Products by Development Phase 13
Eli Lilly and Company, Performance Chart (2011 - 2015) 60
Eli Lilly and Company, Ratio Charts 62
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 63
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 64

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.